|
Three-year follow-up data from KEYNOTE-966: Pembrolizumab (pembro) plus gemcitabine and cisplatin (gem/cis) compared with gem/cis alone for patients (pts) with advanced biliary tract cancer (BTC). |
| |
|
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; CStone Pharmaceuticals; Eisai; Exelixis; Genentech/Roche; Hengrui Therapeutics; Lilly; Medivir; Medivir; Merck; Pfizer |
Speakers' Bureau - Genentech |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
| |
|
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo/UCB Japan; Eisai; Incyte; J-pharma; MSD; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Consulting or Advisory Role - Boehringer Ingelheim; Novocure |
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); chio (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); Incyte (Inst); J-pharma (Inst); JPH Clinical Development (Inst); MSD (Inst); Novartis (Inst); Novocure (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst) |
| |
|
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; Roche/Genentech; SERVIER |
Research Funding - AstraZeneca; Bayer; Boryung Pharmaceuticals; CKD pharm; Eisai; Lunit; SERVIER |
| |
|
Consulting or Advisory Role - AstraZeneca; GlaxoSmithKline; MSD; Roche |
Research Funding - MSD (Inst) |
| |
|
Honoraria - Astellas Pharma; AstraZeneca; Bayer Yakuhin; Chugai Pharma; Daiichi Sankyo; EA Pharma; Eisai; Fujifilm; Incyte Japan; Lilly Japan; MSD; Nihon Servier; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Teijin Pharma; Yakult Honsha |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Delta-Fly Pharma; Eisai; Fujifilm; J-Pharma; MSD; OncoTherapy Science; Ono Pharmaceutical |
| |
|
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); J-Pharma; Kinnate Biopharma; Merck (Inst); Moderna Therapeutics; Regeneron; Tyra Biosciences |
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Merck |
| |
|
Honoraria - AstraZeneca; Eisai; MSD; Roche |
Consulting or Advisory Role - AstraZeneca; BMS; Eisai; MSD Oncology; Roche |
Research Funding - Eisai; MSD |
Travel, Accommodations, Expenses - Ipsen; Roche |
| |
|
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Basilea; Bayer; BeiGene; Boston Scientific; Bristol-Myers Squibb; BTG; Eisai; Incyte; Ipsen; Merck Serono; MSD; Roche; SERVIER; Taiho Oncology |
Research Funding - Beigene (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Exeliom Biosciences |
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - AstraZeneca; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD Oncology |
Consulting or Advisory Role - Bristol-Myers Squibb |
| |
|
Consulting or Advisory Role - Bayer; Ipsen; Roche; SERVIER |
|
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Bayer; Ipsen; Servier |
| |
|
Honoraria - AstraZeneca; Bayer; Eisai; MSD; Novartis; Ono Pharmaceutical; Pfizer; SERVIER; Taiho Pharmaceutical; Takeda; Yakult Honsha |
| |
|
Honoraria - Bayer Schering Pharma |
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; Bristol-Myers Squibb; Eisai; Ipsen; Roche; SERVIER; Sirtex Medical; Taiho Pharmaceutical |
Speakers' Bureau - Bayer; Roche; SIRTEX Medical |
Research Funding - AstraZeneca (Inst); Bayer Schering Pharma (Inst); BMS GmbH & Co. KG (Inst); Incyte (Inst); Merck (Inst); MSD (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Ipsen; Roche |
| |
|
Consulting or Advisory Role - ABL Bio; Adicet Bio; Arcus Biosciences; AstraZeneca; Celgene; ImmuneOncia; Intocell; MediRama; Merck Serono; SERVIER |
Research Funding - ABL Bio; Celgene; Eutilex; medpacto; SERVIER |
Travel, Accommodations, Expenses - Minneamrita Therapeutics |
| |
|
Honoraria - Amgen; AstraZeneca/MedImmune; BeiGene; Boehringer Pharma GmbH; Boston Scientific; Bristol-Myers Squibb; Daichi-Sankyo; Eisai; GlaxoSmithKline; Incyte; Ipsen; Janssen; Lilly; MSD; Pierre Fabre; Roche; SERVIER; Sirtex Medical; Sirtex Medical; Taiho Oncology; TERUMO |
Consulting or Advisory Role - Amgen; AstraZeneca; Baxalta; Boehringer Pharma GmbH; BTG; Daichi-Sankyo; EISAI; Incyte; IPSEN; Lilly; Novartis; Pierre Fabre; Roche; Sirtex Medical; Taiho Oncology; Taiho Oncology; Terumo |
Research Funding - Novartis |
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Lilly; MSD; Roche |
| |
|
Consulting or Advisory Role - Aptitude Health; AstraZeneca; Autem Medical; Baxter; Boehringer Ingelheim; Cantargia AB; Debiopharm Group; Delcath Systems; Genoscience Pharma; Hutchison MediPharma; Imaging Equipment Limited; Incyte; Ipsen; Keocyt; Medivir; Merck; Mundipharma; Novartis; Nucana; PCI Biotech; Pfizer; Pieris Pharmaceuticals; QED Therapeutics; SERVIER; Sirtex Medical; Taiho Oncology; Wren Laboratories; Zymeworks |
Speakers' Bureau - Delcath Systems; Imaging Equipment Limited; Incyte; Ipsen; Mylan; Novartis; Nucana; SERVIER |
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Lilly; Nucana; Roche |
| |
|
|
Stock and Other Ownership Interests - Merat and Co., Inc. |
| |
|
|
Stock and Other Ownership Interests - Merck |
| |
|
|
Stock and Other Ownership Interests - Merck |
| |
|
No Relationships to Disclose |